Metagenomi Therapeutics to Present at Wells Fargo Healthcare Conference

EMERYVILLE, Calif., Sept. 01, 2026 /CourierPR/ -- Metagenomi Therapeutics, Inc., an in vivo genome editing company, will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, Massachusetts, on September 10, 2026. Jian Irish, Ph.D., M.B.A., the company’s President and CEO, will participate in a fireside chat at 12:45 p.m. Eastern Time.

The presentation will be accessible on the company’s website under the “News & Events” section of the Investors page. Metagenomi Therapeutics specializes in developing curative genetic medicines using proprietary technologies, with a focus on metagenomics, the study of genetic materials from the natural environment. The company’s lead program, MGX-001, is a potential breakthrough treatment for hemophilia A, showing promising preclinical results that could provide a life-long cure.

MGX-001 is designed to offer a one-time, curative treatment that prevents bleeding events and joint damage in both adults and children with hemophilia A. The company is also exploring the use of its site-specific genome integration system and partnered assets to address cardiometabolic diseases. According to the company, the MGX-001 program has the potential to establish a new standard of care for hemophilia A treatment.

Metagenomi Therapeutics was founded on the science of metagenomics and aims to develop novel CRISPR gene-editing tools that can correct any genetic mutation in the human genome. The company is dedicated to expanding its pipeline through its proprietary genetic editing capabilities, focusing on high-value disease indications with clear clinical and regulatory pathways.